Bevacizumab injection
Products billed under this code include Avastin.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Avastin.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Avastin | Genentech, Inc. | 50242-0060-01 | 10 | $754.92 |
| Avastin | Genentech, Inc. | 50242-0061-01 | 40 | $3,019.68 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $75.492 | +$0.669 | 10 MG | Bevacizumab injection | v1, posted September 17, 2026 |
| 3Q26 | $74.823 | +$0.468 | 10 MG | Bevacizumab injection | v1, posted September 15, 2026 |
| 2Q26 | $74.355 | +$0.723 | 10 MG | Bevacizumab injection | v1, posted September 15, 2026 |
| 1Q26 | $73.632 | +$0.431 | 10 MG | Bevacizumab injection | v1, posted September 15, 2026 |
| 4Q25 | $73.201 | +$0.152 | 10 MG | Bevacizumab injection | v1, posted September 8, 2026 |
| 3Q25 | $73.049 | +$0.321 | 10 MG | Bevacizumab injection | v1, posted March 10, 2026 |
| 2Q25 | $72.728 | −$0.462 | 10 MG | Bevacizumab injection | v1, posted March 10, 2026 |
| 1Q25 | $73.19 | +$0.486 | 10 MG | Bevacizumab injection | v1, posted December 19, 2025 |
| 4Q24 | $72.704 | +$0.242 | 10 MG | Bevacizumab injection | v1, posted June 11, 2025 |
| 3Q24 | $72.462 | −$1.694 | 10 MG | Bevacizumab injection | v1, posted June 11, 2025 |
| 2Q24 | $74.156 | +$0.083 | 10 MG | Bevacizumab injection | v1, posted March 11, 2025 |
| 1Q24 | $74.073 | +$0.263 | 10 MG | Bevacizumab injection | v1, posted December 19, 2024 |
| 4Q23 | $73.81 | +$0.231 | 10 MG | Bevacizumab injection | v1, posted October 10, 2024 |
| 3Q23 | $73.579 | +$2.225 | 10 MG | Bevacizumab injection | v1, posted June 5, 2024 |
| 2Q23 | $71.354 | +$0.602 | 10 MG | Bevacizumab injection | v1, posted February 23, 2024 |
| 1Q23 | $70.752 | +$1.03 | 10 MG | Bevacizumab injection | v1, posted December 6, 2023 |
| 4Q22 | $69.722 | +$0.497 | 10 MG | Bevacizumab injection | v1, posted June 22, 2023 |
| 3Q22 | $69.225 | −$0.266 | 10 MG | Bevacizumab injection | v1, posted June 9, 2023 |
| 2Q22 | $69.491 | +$1.63 | 10 MG | Bevacizumab injection | v1, posted December 14, 2022 |
| 1Q22 | $67.861 | −$2.551 | 10 MG | Bevacizumab injection | v1, posted June 8, 2022 |
| 4Q21 | $70.412 | −$0.183 | 10 MG | Bevacizumab injection | v1, posted June 2, 2022 |
| 3Q21 | $70.595 | −$1.919 | 10 MG | Bevacizumab injection | v1, posted June 2, 2022 |
| 2Q21 | $72.514 | −$3.234 | 10 MG | Bevacizumab injection | v1, posted March 1, 2022 |
| 1Q21 | $75.748 | – | 10 MG | Bevacizumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.